Jiayu Wang, Binghe Xu, Quchang Ouyang, Zhihong Wang, Qingyuan Zhang, Yu Ren, Jincai Zhong, Tao Sun, Zhongsheng Tong, Wenxian Zhou, Xiaojia Wang, Yahua Zhong, Xiaohua Zeng, Yuee Teng, Jing Sun, Yunhong Xia, Cuizhi Geng, Fuming Qiu, Huadong Zhao, Ning Liao. "ETER901: A randomized, open-label, phase III trial of anlotinib in combination with anti-PD-L1 antibody benmelstobart (TQB2450) versus nab-paclitaxel in first-line treatment of recurrent or metastatic triple-negative breast cancer.." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.16_suppl.1104